Allometric scaling vs PBPK: when each approach helps in human dose prediction
Compare allometric scaling and PBPK for human dose prediction using in vivo data and mechanistic models. Read more.
From PBPK modeling to first-in-human dose: how predictive DMPK can reduce early clinical risk
Explore how PBPK modeling supports human PK prediction, first-in-human dose selection, and model-informed drug development. Read more.
Engineering Oral Solid Dosage Forms to Enhance Therapeutic Efficiency & Patient Acceptability
Explore how Syngene improves bioavailability, extended release and patient adherence in oral solid dosage forms. Watch the webinar.